Prescription ranitidine use and population exposure in 6 Canadian provinces, 1996 to 2019: a serial cross-sectional analysis

BACKGROUND: Ranitidine was the most prescribed histamine-2 receptor antagonist (H(2)RA) in Canada when recalled in 2019 because of potential carcinogenicity. We sought to compare geographic and temporal patterns in use of prescription ranitidine and 3 other HRAs and estimated population exposure to...

Descripción completa

Detalles Bibliográficos
Autores principales: Levy, Adrian R., Stock, David, Paterson, J. Michael, Tamim, Hala, Chateau, Dan, Quail, Jacqueline, Ronksley, Paul E., Carney, Greg, Reynier, Pauline, Targownik, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: CMA Impact Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635705/
https://www.ncbi.nlm.nih.gov/pubmed/37935487
http://dx.doi.org/10.9778/cmajo.20220131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635705/
https://www.ncbi.nlm.nih.gov/pubmed/37935487
http://dx.doi.org/10.9778/cmajo.20220131

Ejemplares similares